

Faculty

Prof. Dr. med. Björn Chapuy
*Medical clinic for Hematology, Oncology
and Tumor Immunology | CBF
Charité - University Medicine
Berlin, Germany*

Dr. med. Johannes Düll
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Florian Eisele, MD
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Pieterella Lugtenburg MD, PhD
*Erasmus MC - Cancer Institute
Rotterdam, The Netherlands*

Dr. rer. nat. Manja Meggendorfer
*MLL Münchner Leukämielabor GmbH
München, Germany*

PD Dr. med. habil. Michael Oertel
*Clinic for Radiotherapy - Radiooncology
University Clinic Münster
Münster, Germany*

PDr. med. Maximilian Scheifele
*Klinik und Poliklinik für Nuklearmedizin
LMU Klinikum
München, Germany*

Professeur Catherine Thieblemont
*Hemato-Oncologie
Hôpital Saint-Louis
Paris, France*

Prof. Dr. med. Max Topp
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Jason Westin, MD, MS, FACP
*Department of Lymphoma - Myeloma
Division of Cancer Medicine
University of Texas MD Anderson
Cancer Center
Houston, TX, USA*

Scientific Chair/Host

Dr. med. Johannes Düll

Venue

Hotel Melchior Park
Am Galgenberg 49
97074 Würzburg
Germany
Web: <https://t1p.de/melchior>

With the kind support of our sponsors

abbvie



An event of

Academy2 GmbH & Co. KG
Fürther Straße 33
90513 Zirndorf, Germany
Web: <https://cmeducation.de/>
E-mail: events@academy2.de

The contents of this event are designed to be product and service neutral. The organizer confirms, that the scientific chair and the speakers will disclose potential conflicts of interest to the participants. The event is sponsored by the following supporters:

AbbVie Deutschland GmbH & Co. KG with an amount of 18.000€, Swedish Orphan Biovitrum GmbH, with an amount of 15.000€, Incyte Biosciences Germany GmbH with an amount of 10.000€, AstraZeneca GmbH with an amount of 10.000€, Bristol-Myers Squibb GmbH & Co. KGaA with an amount of 10.000€, BeOne Medicines Germany GmbH with an amount of 7.760€, Roche Pharma AG with an amount of 5.000€, Gilead Sciences GmbH with an amount of 2.500€, The total expenses of the event amount to 78.260.00€.

INVITATION & PROGRAM

Insights in DLBCL: New Horizons 2026

Friday 05.06.2026

Saturday 06.06.2026

Live in Würzburg and online!

Register now!

– Participation is free –



To get to the registration,
click on the button
or scan the QR code.

<https://qrco.de/DLBCL2026>

CME-certification is pending

Uniklinikum
Würzburg



Welcome letter

Dear colleagues,
Ongoing advances continue to refine the management of patients with diffuse large B-cell lymphoma (DLBCL). Data presented at the most recent ASH Annual Meeting provided substantial evidence on the role of bispecific antibodies and CAR T-cell therapies, both from pivotal clinical trials and real-world experience, further reinforcing immunotherapy as a key component of contemporary DLBCL treatment.
Current discussions increasingly focus on rational combination strategies, optimized management of immune-based therapies, and the appropriate sequencing of available treatment modalities across different disease settings.
With our DLBCL Congress, we are pleased to offer a scientific platform for multidisciplinary exchange, critical discussion of emerging data, and shared learning among colleagues, with the goal of translating evidence into clinical practice.
We warmly invite you to participate – either on site in Würzburg or live via online stream – and look forward to a highly informative meeting and a stimulating exchange of perspectives.

Best regards,



Johannes Düll
Senior physician
Universitätsklinik Würzburg



Register now!
– Participation is free –

<https://qrco.de/DLBCL2026>

Scientific Program

Friday, June 5th 2026

- 15:00 – 15:10 **Welcome and introduction**
Dr. med. Johannes Düll
- 15:10 – 15:40 **What's hot and what's not? DLBCL-specific highlights of ASH 2025**
Prof. Dr. med. Max Topp
- 15:40 – 16:10 **ctDNA – a new approach in the field – The concept of rolling reporter**
Dr. rer. nat. Manja Meggendorfer,
Dr. med. Johannes Düll
- 16:10 – 16:40 **FDG PET vs. ctDNA MRD. Will PET survive? Or do we need imaging follow ups?**
Dr. med. Maximilian Scheifele
- 16:40 – 17:00 **Debate: Nuclearmedizin vs. MRD approach**
- 17:00 – 17:30 Coffee break
- 17:30 – 18:10 **The future is now? Chemofree for everyone in first line and possible sequencing strategies**
Professor Jason Westin
- 18:10 – 19:00 **Deep dive into bridging radiotherapy – revisiting concepts, fields and doses**
PD Dr. med. habil. Michael Oertel
- 19:00 – 21:30 Dinner

Saturday, June 6th 2026

- 9:00 – 9:45 **Second line DLBCL: CAR T for everyone? CAR T vs. Bispecs and chemofree: which treatment fits for which patient?**
Professor Catherine Thieblemont
- 9:45 – 10:30 **Post CAR T and beyond: alternativ treatments and combinations needed – new hope in later lines?**
Professor Pieterella Lugtenburg, MD, PhD
- 10:30 – 10:45 Coffee break
- 10:45 – 11:30 **First line treatment: Bispec, small molecules and ADCs: what will change the future treatment landscape in DLBCL**
Prof. Dr. med. Björn Chapuy
- 11:30 – 12:15 **Case studies (second line/third line and beyond) with focus on treatment decision and sequencing of therapies**
Florian Eisele, MD
- 12:15 – 12:45 **AbbVie-sponsored talk: Elevating standards: Treatment management strategies of bispecific antibodies in DLBCL**
tba*
- 12:45 – 13:00 **Conclusion and Farewell**
Dr. med. Johannes Düll

*to be announced